MS. Multiple sclerosis
Conditions
Interventions
Intervention 1: Intervention group: Patients in this group use 50 mg trazodone tablets of Tehran Shimi Company every night at 9 o'clock from the first day of hospitalization until the day of discharge
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Patients with relapsing-remitting MS who are between 18 and 65 years old and hospitalized for treatment with corticosteroid pulse. Hospitalized patients who are candidates for corticosteroid pulse at the rate of 1 gram per day for 3 to 5 days.
Exclusion criteria
Exclusion criteria: Receiving other sleeping pills such as Barbiturates, Benzodiazepines, Doxepin, Melatonin and Zolpidem in the last 2 weeks Having Primary Insomnia Trazodone use in the last 2 weeks Taking Monoamine oxidase inhibitor drugs in the last 2 weeks History of hypersensitivity reaction to Trazodone or any components in the formulation Severe chronic renal failure (Creatinine clearance less than 30 ml/min) and liver failure Pregnancy and lactation Patients receiving concomitant Intravenous immunoglobulin or plasma exchange other than Corticosteroid pulse
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Insomnia score in Verran and Snyder-Halpern questionnaire (VSH). Timepoint: Every day from the first day of hospitalization until the day of discharge (A total of 3 to 5 days). Method of measurement: VSH questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHooshyar Honarmand
Tehran University of Medical Sciences
Outcome results
None listed